FMP
Jan 15, 2026
H.B. Fuller Company, listed on the NYSE:FUL, is a global adhesives manufacturer. The company specializes in providing adhesive solutions for various industries, including construction, packaging, and electronics. FUL competes with other adhesive manufacturers like 3M and Henkel. The company recently reported its financial results for the quarter ending November 2025.
On January 14, 2026, FUL announced earnings per share (EPS) of $1.28, exceeding the estimated $1.24. This represents a significant increase from the previous year's EPS of $0.92. Despite this positive EPS performance, the company's revenue of approximately $894.8 million fell short of the estimated $901.3 million, as highlighted by Zacks.
The reported revenue of $894.8 million for the fourth quarter marks a 3.1% decline compared to the same period last year. However, when adjusted for the flooring divestiture, net revenue actually increased by 0.9% year-on-year. The gross margin improved to 31.5%, with an adjusted gross margin of 32.5%, driven by favorable pricing and raw material cost actions.
FUL's financial metrics provide insight into its market valuation. The company has a price-to-earnings (P/E) ratio of approximately 30.77, indicating how the market values its earnings. The price-to-sales ratio is nearly 1, suggesting that its market capitalization is roughly equal to its total sales. The enterprise value to sales ratio stands at about 1.56.
The company's financial health is further reflected in its debt-to-equity ratio of about 1.06, showing its use of debt financing relative to equity. Additionally, the current ratio of approximately 1.93 suggests FUL's ability to cover short-term liabilities with short-term assets. These metrics are crucial for investors assessing the company's performance and future prospects.
MoonLake Immunotherapeutics, trading on NASDAQ under the symbol MLTX, is a clinical-stage biotechnology company. It focu...
TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company focused on developing and commercializing treatments ...